Introduction/Background*Cancer of the cervix is one of the most common cancers in women worldwide. According to GLOBOCAN data of 2020, there were 604,127 new cases of cervical cancer and 341,831 deaths due to the same. This shows that the burden of cervical cancer is still high and further research and implementation of screening programs can help us eliminate this cancer from the world. In our study we have evaluated patients with early-stage cervical cancer who had been treated by surgery followed by risk based tailored adjuvant therapy in our Centre. The clinicopathological features and survival outcomes of these patients were evaluated. These patients were restaged as per new FIGO 2018 staging and its impact on survival evaluated.

Methodology A retrospective study conducted from 1^st June 2013 to 31^st May 2018 in a tertiary care hospital in North India. All patients of early stage (1B1 to IIA1) cervical cancer who underwent primary surgery followed by tailored adjuvant therapy were analyzed. The overall survival and relapse free survival were calculated. On the basis of histopathology reports, reclassification was done into new FIGO 2018 stage. The survival outcome of both groups was then calculated and compared.

Result(s)*100 patients of early-stage cancer cervix were studied. All patients underwent open radical hysterectomy with bilateral pelvic lymph node dissection. The median age of the study population was 52.5 years. With a median follow up of 62.1 months the overall survival and relapse free survival was 87.5% and 92.3% respectively. The study population was then reclassified according to new FIGO 2018 staging. It was seen that the patients with stage IB1and IB2 cervical cancer had overall survival of 91.1% and 90% respectively. The overall survival of stage IB3 was 80% and the survival of stage IIIC1 was only 60%.

Conclusion*The new FIGO 2018 staging classification has a significant effect on survival outcome when lymph nodes are involved and also in prognostication of patients with cancer cervix. Surgery followed by risk based appropriate adjuvant therapy is able to provide favorable overall and relapse free survival.